Swiss dermatology company Galderma, which will debut at this year's China International Import Expo, said it will introduce another nine medical beauty products, six skin care products, and a dermatitis therapy to the China market by 2024.

The decision to participate in the fourth CIIE, which will be held in Shanghai in November, is in line with the company's strategy to accelerate its introduction of high-quality products to the country at a time when the domestic medical aesthetics market is undergoing rapid development, said Lainey Lei, general manager of Galderma China, during an interview with China Daily on Wednesday.

"We forecast the entire medical cosmetology market to maintain strong growth over the coming five years. The compound annual growth rate of botulinum toxin and hyaluronic acid injections is estimated at 12 percent, and that for the wider spectrum of products will be higher," she said.

China had over 15 million individuals seeking beauty treatments by the end of 2020, according to a report published by domestic medical aesthetics platform So-Young International.

"Two trends over the past two years were the obvious increase of youngsters aged around 20 seeking medical beauty treatment and people pursuing personalized solutions," she said.

Lei also noted that the number of male users of medical cosmetology in China has risen from 5 percent five years ago to 17 percent today.

Established in 1981, Galderma will exhibit innovative products in the fields of medical beauty, daily skin care, and treatment at the CIIE. Its major exhibits will include a hyaluronic acid product for nasal reshaping, the first of its kind to gain market approval in China in April, lidocaine-based solutions for painless facials and shaping, and the first amino acid-based cleanser tailor-made for Chinese consumers, especially those with sensitive skin.

Some products that have not entered the China market or are still in the research and development phase, including a liquid botulinum toxin and a medical therapy to treat atopic dermatitis, will also be exhibited.

"We believe that the open and win-win platform of CIIE will help us better serve customers and patients with innovative solutions and achieve deeper communication and interactions with industry partners and customers," said Lei.

By Zhou Wenting